GEMoaB Announces the Appointment of Oncology Expert Michael Pehl as Chief Executive Officer

 
Michael_Pehl_900x600px.jpg

Dresden, Germany 16/07/2019

Today GEMoaB GmbH, a biopharmaceutical company that focuses on discovery, development, manufacturing and commercialization of next generation immunotherapies for hard-to-treat cancers, announced the appointment of Michael Pehl as its new CEO, effective as of July 1st, 2019. This reflects GEMoaB’s strategy to position itself as a fully integrated biotech company for long-term success, building on the strong science and R&D foundation of the company. 

“We are excited that such an oncology-experienced industry executive like Michael will lead GEMoaB to its next stage of growth. Led by Michael, GEMoaB will continue to progress its next generation and proprietary immunotherapy platforms of Affinity-Tailored Adapters for T-Cells (ATAC) such as GEM333 and GEM3PSCA as well as cellular immunotherapies (UniCAR/RevCAR) into the clinic to significantly improve outcomes of patients with hard-to-treat blood cancers and solid tumors”, said Professor Dr. med. Gerhard Ehninger, Company Founder and Co-Owner. “I have known Michael for many years. He is science focused, highly experienced and well positioned to lead and develop GEMoaB and its exceptional staff, pipeline and partnerships.” 

Mr. Pehl brings to GEMoaB over 25 years of international biotechnology and oncology leadership experience in both the U.S. and Europe. He joins GEMoaB from Immunomedics Inc., where he served as Chief Executive Officer, leading the implementation of the development plan and the regulatory submission of the core product sacituzumab govetecan in metastatic triple negative breast cancer. 

Previously, Michael Pehl had been President of Oncology at Celgene, as such responsible for the company’s global commercial, clinical development and medical strategy and operations. During that time, Mr. Pehl had been crucial for the development of the pipeline and continued growth in global sales. His responsibility included global clinical programs and commercial launches of drugs like lenalidomide (Revlimid®), pomalidomide (Pomalyst®; Imnovid®) and enasidenib (IDHIFA®) in hematological malignancies, nab-paclitaxel (Abraxane®) in solid tumors and luspatercept in MDS and beta-thalassemia. 

Prior to this role, Mr. Pehl had served Celgene as Senior Vice President, Global Marketing and Strategy; Head of Global Marketing; Head of Hematology Europe; Vice President Central and Eastern Europe & Middle East and General Manager Germany. 

His industry career started at AMGEN where he had held German and European commercial leadership roles in Oncology and Nephrology. 

“I am grateful that I have been provided with the opportunity to head GEMoaB and work with its outstanding team during such an exciting and transformative time,” said Michael Pehl. “With its truly differentiated next generation immunotherapy platforms and its evolving pre-clinical and clinical pipeline, GEMoaB is extremely well positioned for future success. Together with our partners and potential investors, it is my goal to progress GEMoaB into a fully integrated biopharmaceutical company that will help to improve the outcomes of cancer patients in currently heavily underserved indications.” 

For further information, please contact:

Constanze Medack 

Email: c.medack@gemoab.com
Tel.: +49 351 4466-45027 

Investor Contact 

Michael Pehl 

Email: m.pehl@gemoab.com
Tel.: +49 351 4466-45030 

 
Jan Paul